Close Menu

NEW YORK – As the diagnostics space trends more toward liquid biopsy, companies are shifting focus from using the technology to detect advanced stage disease to trying to discover earlier stage disease.

Foundation Medicine, a Roche subsidiary, took a step in that direction with its acquisition of Lexent Bio earlier this month, a decision that stemmed from "a desire to have more of a multiomic approach to our diagnostic portfolio," said Foundation's Chief Scientific Officer Priti Hegde.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.